Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial-Reference-Cited by-同舟云学术

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial

Published:2023-08 Issue:2 Volume:84 Page:156-163
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Sartor Oliver,Karrison Theodore G.,Sandler Howard M.,Gomella Leonard G.,Amin Mahul B.,Purdy James,Michalski Jeff M.,Garzotto Mark G.,Pervez Nadeem,Balogh Alexander G.,Rodrigues George B.,Souhami Luis,Reaume M. Neil,Williams Scott G.,Hannan Raquibul,Jones Christopher U.,Horwitz Eric M.,Rodgers Joseph P.,Feng Felix Y.,Rosenthal Seth A.

Funder

National Cancer Institute

Sanofi

Publisher

Elsevier BV

Subject

Urology

Reference25 articles.

1. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

2. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol;Attard;Lancet,2022

3. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial;Clarke;Ann Oncol,2019

4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial;Kyriakopoulos;J Clin Oncol,2018

5. Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial;Rosenthal;J Clin Oncol,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scaling and interpreting treatment effects in clinical trials using restricted mean survival time;Clinical Trials;2024-06-13

2. Artificial intelligence in radiotherapy: Current applications and future trends;Diagnostic and Interventional Imaging;2024-06

3. What is the key factor determining effectiveness of radiotherapy for high-risk prostate cancer: a hidden message from RTOG 0521;Translational Andrology and Urology;2024-04

4. Approach to Patients with High-Risk Localized Prostate Cancer: Radiation Oncology Perspective;Current Treatment Options in Oncology;2024-01

5. Les grands principes des traitements du cancer de prostate localisé;Médecine Nucléaire;2023-11